Skip to main content
Arbutus Biopharma Corp logo

Arbutus Biopharma Corp — Investor Relations & Filings

Ticker · ABUS ISIN · CA03879J1003 US Manufacturing
Open in API
Filings indexed 1,013 across all filing types
Latest filing 2026-05-27 Declaration of Voting R…
Country US United States of America
Listing US ABUS

About Arbutus Biopharma Corp

https://www.arbutusbio.com/

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company focused on developing therapeutics for viral diseases, with a primary emphasis on creating a functional cure for chronic Hepatitis B virus (cHBV) infection. The company's strategy involves developing combination regimens that utilize multiple agents with complementary mechanisms of action. This approach aims to suppress viral replication, reduce viral antigens, and reawaken the host's immune response. A key candidate in its pipeline is imdusiran, an RNA interference (RNAi) therapeutic. Arbutus leverages its expertise in virology and drug delivery systems to advance its portfolio of clinical assets for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a current report on Form 8-K filed under the Securities Exchange Act, specifically Item 5.07 “Submission of Matters to a Vote of Security Holders.” It provides the detailed vote counts on shareholder proposals at the Annual Meeting, including director elections and plan adoption. This aligns with the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-27 English
10-Q - Arbutus Biopharma Corp (0001447028) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-13 English
8-K - Arbutus Biopharma Corp (0001447028) (Filer)
Earnings Release Classification · 99% confidence The document is a Form 8-K current report under Item 2.02 (Results of Operations and Financial Condition) furnishing a press release with first quarter 2026 financial results. This corresponds to an initial earnings announcement rather than a full interim report or other filing. Therefore, it fits the Earnings Release category. Q1 2026
2026-05-13 English
8-K - Arbutus Biopharma Corp (0001447028) (Filer)
Regulatory Filings
2026-04-15 English
DEF 14A - Arbutus Biopharma Corp (0001447028) (Filer)
Proxy Solicitation & Information Statement
2026-04-14 English
8-K - Arbutus Biopharma Corp (0001447028) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and states that a press release announcing financial results for the fourth quarter and year ended December 31, 2025, is furnished as an exhibit. The document itself does not contain detailed financial statements or analysis but rather references a press release with key financial highlights. The length is 3332 characters, which is relatively short and consistent with a current report rather than a full financial report. According to the classification rules, an 8-K with financial results announcement corresponds to an Earnings Release (ER) since it is the initial announcement of quarterly/periodical financial results with key highlights only.
2026-03-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.